PARP inhibitors can selectively kill tumor cells with HR function defects caused by RBCA1 and BRCA2 genes mutation by inhibiting PARP activity and leading to DNA repair failure, but have no effect on normal cells, which is synergistic lethal effect (Lord and Ashworth, 2017). Here, BRCA2 is linked to neoplasm.